JP2025505994A - プロテインチロシンホスファターゼ阻害剤およびその使用 - Google Patents

プロテインチロシンホスファターゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP2025505994A
JP2025505994A JP2024546072A JP2024546072A JP2025505994A JP 2025505994 A JP2025505994 A JP 2025505994A JP 2024546072 A JP2024546072 A JP 2024546072A JP 2024546072 A JP2024546072 A JP 2024546072A JP 2025505994 A JP2025505994 A JP 2025505994A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
pharma
cycloalkyl
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505994A5 (https=
Inventor
ローランド，ジェイソン
ジー． デュロン，セルジオ
Original Assignee
ネリオ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネリオ セラピューティクス，インク． filed Critical ネリオ セラピューティクス，インク．
Publication of JP2025505994A publication Critical patent/JP2025505994A/ja
Publication of JP2025505994A5 publication Critical patent/JP2025505994A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024546072A 2022-02-02 2023-02-01 プロテインチロシンホスファターゼ阻害剤およびその使用 Pending JP2025505994A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305788P 2022-02-02 2022-02-02
US202263305783P 2022-02-02 2022-02-02
US63/305,788 2022-02-02
US63/305,783 2022-02-02
PCT/US2023/012092 WO2023150150A1 (en) 2022-02-02 2023-02-01 Protein tyrosine phosphatase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025505994A true JP2025505994A (ja) 2025-03-05
JP2025505994A5 JP2025505994A5 (https=) 2026-02-09

Family

ID=87552845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546072A Pending JP2025505994A (ja) 2022-02-02 2023-02-01 プロテインチロシンホスファターゼ阻害剤およびその使用

Country Status (4)

Country Link
US (1) US20250134882A1 (https=)
EP (1) EP4472957A4 (https=)
JP (1) JP2025505994A (https=)
WO (1) WO2023150150A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506400A (ja) * 2022-02-02 2025-03-11 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250090365A (ko) * 2022-11-09 2025-06-19 브리스톨-마이어스 스큅 컴퍼니 암 질환의 치료를 위한 단백질 티로신 포스파타제 (ptpn2)의 억제제로서의 인다졸 치환된 1,2,5-티아디아졸리딘 유도체
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
AU2024288616A1 (en) * 2023-07-11 2026-02-12 Shenzhen Zhongge Biological Technology Co., Ltd. Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof
CN121889379A (zh) * 2023-09-15 2026-04-17 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
KR20150118158A (ko) * 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
MX2023002953A (es) * 2020-09-11 2023-06-01 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
WO2022192598A1 (en) * 2021-03-11 2022-09-15 Kumquat Biosciences Inc. Heterocycles and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506400A (ja) * 2022-02-02 2025-03-11 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用

Also Published As

Publication number Publication date
EP4472957A1 (en) 2024-12-11
WO2023150150A1 (en) 2023-08-10
US20250134882A1 (en) 2025-05-01
EP4472957A4 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
JP2025505994A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025513882A (ja) タンパク質チロシンホスファターゼ阻害剤およびその使用
JP2025507292A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025506400A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2021526123A (ja) オートタキシン阻害剤とその使用
WO2023283373A1 (en) 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof
US20250145624A1 (en) Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US20250188094A1 (en) Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US12103915B2 (en) TEAD inhibitors and methods of uses thereof
TW202525275A (zh) 作為鈉通道調節劑的新型化合物及其用途
WO2024141015A1 (en) Protein tyrosine phosphatase inhibitors and uses thereof
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
TW202510846A (zh) 蛋白質酪胺酸磷酸酶降解劑及其用途
CN118974027A (zh) 蛋白质酪氨酸磷酸酶抑制剂及其用途
WO2026067793A1 (en) Tnik inhibitors for the treatment of pain
WO2025201397A1 (en) Tead inhibitors and methods of uses thereof
CN121443601A (zh) 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法
WO2025232848A1 (en) Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2025152964A1 (en) Novel compounds as glucocorticoid receptor modulators and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260130